Is oligopeptide-1 FDA-approved, and what does the research show?

What is oligopeptide-1?

Epidermal growth factor is a growth factor, a signaling protein that cells release to tell nearby cells to survive, multiply, move and mature ¹⁵. Oligopeptide-1 is the name under which the recombinant version is listed as a cosmetic ingredient, and "sh-oligopeptide-1" marks a version with the human sequence ¹,². Recombinant means the protein is made by cells, such as Escherichia coli bacteria, that carry the human gene ³.

A 2023 review in Cutaneous and Ocular Toxicology describes sh-oligopeptide-1 as "considered to be the bioequivalent" of EGF and questions whether the cosmetic grade is biologically active ¹⁶. It is sold in face serums and other skin-care products ¹,². In South Korea a recombinant EGF solution is a prescription drug, approved in 1997 and today indicated for diabetic foot ulcers ³.

Is oligopeptide-1 FDA-approved?

No. Oligopeptide-1 is not FDA-approved: Drugs@FDA lists no approved epidermal growth factor product under that name, "EGF" or "oligopeptide-1" as of November 9, 2026 ⁴. It is sold as a cosmetic ingredient ¹,². FDA's page on its authority over cosmetics, current as of November 18, 2025, says "The law does not require cosmetic products and ingredients, other than color additives, to have FDA approval before they go on the market" ⁵.

The companies that make or market a cosmetic "have a responsibility to ensure the safety of their products" ¹⁷. The Modernization of Cosmetics Regulation Act of 2022 gave FDA a recall power, on a condition: a "reasonable probability that a cosmetic is adulterated or misbranded" and that it "will cause serious adverse health consequences or death" ¹⁷. FDA then "has the authority to order a mandatory recall if the responsible person refuses to do so voluntarily" ¹⁷. So a serum carrying it reaches you with no FDA review of its safety or effectiveness before sale ⁵.

Whether a product is a cosmetic or a drug "is determined by a product's intended use" ¹⁸. FDA lists claims that a product will "regenerate cells" among those that make it a drug ¹⁸. On wrinkles, FDA writes that a product "intended to make lines and wrinkles less noticeable, simply by moisturizing the skin" is a cosmetic ¹⁹. One "intended, for example, to remove wrinkles or increase the skin's production of collagen" is "a drug or a medical device" ¹⁹.

FDA has applied that test to at least one product containing EGF. In a June 2024 warning letter to the sunscreen's South Korean manufacturer, FDA called a sunscreen marketed with sh-oligopeptide-1 for "advanced defense against aging and cell damage" an "unapproved new drug" ². Such claims, FDA wrote, represented the growth factors as active ingredients "intended to furnish pharmacological activity" ².

Elsewhere, EGF has been approved as a drug. South Korea's Ministry of Food and Drug Safety lists Easyef, a 0.005 percent recombinant human EGF solution from Daewoong, as a prescription drug ³. Its record is in Korean and is given here in our translation ³. It was approved on March 4, 1997, for diabetic foot ulcers in patients with high blood sugar ³. The label's entry test was a fasting blood sugar of 140 mg/dL or more, or an HbA1c, a three-month blood-sugar measure, over 8 percent ³.

Drugs@FDA holds one approved growth-factor gel for skin wounds, becaplermin (Regranex), a platelet-derived growth factor and a different protein ²⁰. No prescription route for EGF in the United States appears in any source opened. FDA keeps two lists of bulk substances nominated for pharmacy compounding, under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The lists, updated May 14, 2026, and March 21, 2025, do not name it, as read on November 10, 2026.

See the FDA status of every peptide, updated weekly.

How does oligopeptide-1 work?

The proposed mechanism is the one EGF has in wound healing. A review of EGF in dermatology, published online in December 2022, says EGF "plays a pivotal role in wound healing and maintaining tissue homeostasis by regulating cell survival, proliferation, migration, and differentiation" of cells ¹⁵. The authors of the 2026 serum trial say the anti-aging effects of such serums "leverage biological pathways analogous to wound healing" ¹.

Whether a protein in a serum reaches living skin is the open question. In a 2026 study of 20 volunteers, EGF from a cream was measured in the stratum corneum, the dead outer layer ²¹. Its concentration there rose over four weeks to match the product's, and no measurement below that layer is reported ²¹.

The Cutaneous and Ocular Toxicology review argues that the preclinical bioactivity of cosmetic sh-oligopeptide-1 "has not been proven" ¹⁶. An active EGF, it says, would be a potent drug rather than a cosmetic ¹⁶. The dermatology review notes that the number of studies "still remains relatively low" ¹⁵.

What does the research show?

Studied in people: one randomized, double-blinded trial enrolled 20 women aged 50 to 65 with moderate to severe facial photoaging, that is, sun-damaged skin ¹. Neither the women nor the raters knew which serum was which ¹. It ran 12 weeks and was published online in May 2026 ¹. It compared a commercially available oligopeptide-1 serum with a serum made from the fluid in which human skin cells had been grown; there was no placebo arm ¹. Neither group changed on the wrinkle severity scale ¹.

At week 8, investigators rated skin firmness as 26 to 50 percent improved in 90 percent of the oligopeptide-1 group against 20 percent of the comparator group ¹. For skin texture the figures were 80 and 20 percent ¹. By week 12 the between-group differences were no longer statistically significant ¹. Fifty lay raters judged both groups about one to one and a half years younger in the final photographs ¹. DRMTLGY Inc., which sells an oligopeptide-1 serum, funded the study, and the authors call the results "hypothesis-generating" ¹.

Smaller studies of an EGF serum mostly had no control group. Eighteen people with under-eye bags used the serum twice daily for 12 weeks, and 16 finished ⁶. The average grade on a scale of under-eye hollowness fell from 2.06 to 1.63 ⁶. Nine people (eight finished) with pitted (atrophic) acne scars, and then twelve (eleven finished) with darker skin types, used it for 12 weeks, and investigator scores improved ⁷,²².

One of these EGF serum studies was placebo-controlled, a randomized, double-blind split-face study of 15 women with melasma, patches of brown facial pigment ⁸. Each applied the serum to one side of the face and placebo to the other for eight weeks ⁸. Dermatologists rated 73.4 percent of treated sides improved against "13% improvement for the placebo side" ⁸. In a randomized split-face trial, 20 Korean adults with mild to moderate acne used a recombinant EGF cream for six weeks ⁹. Inflammatory lesions fell 33.5 percent and non-inflammatory lesions 25.4 percent on the treated side, while lesions on the control side increased ⁹.

In 52 Korean women split into three groups, a hyaluronic acid microneedle patch carrying EGF improved wrinkles more than the same patch without it over 29 days ¹¹. Sixty women with mild to moderate photoaging took part in a 12-week comparison ¹². A recombinant EGF serum used with a hyaluronic acid serum was set against a marketed serum of spent fibroblast growth media ¹². The blinded investigator preferred the EGF pair on fine lines, radiance and overall appearance by week 12, and the abstract does not say the women were randomized ¹².

A randomized, self-controlled trial enrolled 57 children aged 2 to 14 with atopic dermatitis ¹³. They applied an emulgel of sh-oligopeptide-1 and five other ingredients to one forearm twice daily for 10 days ¹³. Redness and water loss fell on the treated patches of dermatitis; that is a finding about the blend ¹³.

Two randomized split-face trials after laser treatment found no effect on post-laser darkening or wound healing. In 30 Asian patients with Hori's nevus, a form of facial pigmentation, an EGF cream "could not prevent" post-laser darkening over eight weeks ²³. It appeared on 26.7 percent of treated and 20 percent of placebo sides ²³. In 19 patients, an EGF ointment healed laser wounds no faster than petrolatum, and darkening rates did not differ ²⁴.

The larger trials are of EGF as a drug, not a cosmetic. In a South Korean phase 3 trial, the late stage designed to confirm an effect, 167 patients with chronic diabetic foot ulcers were treated at six centers ¹⁰. They received a 0.005 percent recombinant EGF spray or saline twice daily for up to 12 weeks ¹⁰. Ulcers healed completely in 73.2 percent of the EGF group against 50.6 percent of the saline group ¹⁰.

In a multicenter placebo-controlled trial of 89 randomized cancer patients (80 evaluated) with rashes from EGF-receptor-blocking drugs, patients applied an EGF ointment or placebo ¹⁴. Response rates rose with the strength, from 44.4 percent on placebo to 61.5 and 77.8 percent at the two strengths ¹⁴. No placebo-controlled trial of an oligopeptide-1 serum for wrinkles, and no topical cosmetic study longer than 12 weeks, was found as of November 10, 2026.

What are the side effects?

In the 2026 serum trial, the 20 women were checked at each visit for allergic reactions and intolerance, and the authors report no serious adverse events ¹. The 15-woman melasma trial reported no adverse events on either the serum or the placebo side ⁸. The Korean acne trial saw "no severe side effects" in 20 adults over six weeks ⁹. The microneedle patch study in 52 women noted no serious adverse effects ¹¹. These are short studies of small groups, and the Cutaneous and Ocular Toxicology review says cosmetic sh-oligopeptide-1 is sold "with unknown long-term risks" ¹⁶.

The South Korean prescription label, for a 0.005 percent spray applied to ulcers, reports the adverse reactions seen in its trials ³. In its trials, 5.06 percent of treated subjects had an adverse drug reaction ³. Most were pain (3.37 percent) or redness (1.69 percent) where it was applied, with one case each of tissue overgrowth, raised liver enzymes, back pain, muscle pain and neck pain ³. The label bars the drug in patients hypersensitive to it and where there is a systemic or local infection ³. It also bars it in patients who have or have had a malignant tumor at the application site, and calls for caution in patients with a malignant tumor elsewhere ³.

No published study of whether EGF in skin care can cause cancer was found as of November 10, 2026. The drug has not been studied in pregnant or breastfeeding women or in children ³. A Cuban EGF formulation was injected into diabetic foot ulcers in 20 patients ²⁵. The most frequent adverse events were tremors, chills, pain and odor at the injection site, and local infection; that is an injected drug, not a cream ²⁵.

In sport

Neither epidermal growth factor nor oligopeptide-1 is named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency ²⁶. Section S2.3, on growth factors and growth factor modulators, names fibroblast, hepatocyte, insulin-like, mechano, platelet-derived and vascular endothelial growth factors and thymosin-beta 4 ²⁶. Everything in section S2 is prohibited at all times, in and out of competition ²⁶. It then prohibits "other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching" ²⁶. The list does not say whether that clause reaches an EGF skin serum ²⁶.

What JumpstartMD offers

JumpstartMD does not prescribe oligopeptide-1. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.